NEW YORK–(BUSINESS WIRE)–2021 was another banner year for Dalmore Group. The veteran Reg A+ broker continued its trajectory of growth, and more than doubled its prior year’s new clients – as it moved from 85 Reg A+ clients in 2020 to more than 175 through 2021.
And the impressive news does not end there. Dalmore’s current $2B in active Reg A+ deals will be overshadowed by its pipeline of an additional $3B in Reg A+ deals set to roll out in the coming months. This growth is consistent with the upward trend of Dalmore’s Reg A+ deals in 2021, in which Dalmore’s Reg A+ issuers raised over $340M – a disproportionate percentage by a single broker dealer of all such reported deals to date.
Notable Dalmore Reg A+ deals include Gage Cannabis $50M, Flora Growth $29.5M+, Emerald Health Pharmaceuticals $45M+, Juva Life $18M, Draganfly 19M+ and WINC Inc. $11.5M+. And within Dalmore’s active pipeline it supports Ei Ventures with $20M+, Miso Robotics $35M+, Cloudastructure $30M+, Aptera Motors $26M+, Schackelford Pharma $10M+, Legion Works $10M+, Brazil Potash $34M+, and many others.
In March of 2021, the SEC increased Reg A+ limits from $50M to $75M/year (and Reg CF from $1.07M to $5M/year). Dalmore is an industry leader on both platforms. Many of Dalmore’s Reg A+ clients maxed out in their initial raises, and are now on their second offering, seeking up to $75M. Other successful Reg A+ Dalmore clients have gone public after successful Reg A+ offerings.
Dalmore also reports an increase in Security Token Offerings (STO) and Non-Fungible Token (NFT) issuance through Reg A+, in addition to the use of Reg A+ by private REITs as a means to raise capital. And Dalmore has significantly expanded its reach in the area of Reg A+ fractional share “series issuers,” with an industry leading 20 fractional share platform clients to whom Dalmore provides customized primary issuance and secondary market trading services, including secondary market trading…
